Greenwich LifeSciences, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing was signed March 21, 2022. Greenwich is a clinical-stage biopharmaceutical company developing GLSI-100, a combination of GP2 and GM-CSF, intended to prevent breast cancer recurrence. It has no approved products and has generated no revenue.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.56 million | $1.06 million |
| General and administrative expense | $1.04 million | $0.81 million |
| Total operating expenses | $4.60 million | $1.86 million |
| Net loss | $4.57 million | $1.86 million |
| Basic and diluted loss per share | $0.35 | $0.20 |
| Net cash used in operating activities | $4.29 million | $1.15 million |
| Cash at year-end | $27.20 million | $28.66 million |
R&D expense increased 237%, principally due to manufacturing preparation and clinical activities for the planned Phase III trial. G&A expense rose 29%, mainly reflecting increased finance and corporate activities. Cash declined by $1.46 million; $2.84 million of net financing cash flow partly offset operating cash use. The company reported $27.22 million in total assets and $0.39 million in total liabilities at year-end, with no debt balance shown. The filing says existing cash was expected to fund operating and capital needs for at least 12 months from the report date, but would not fund development through regulatory approval. No margins are meaningful given the absence of revenue.
Business, development and material changes
- The planned pivotal program, Flamingo-01, is a Phase III study of GLSI-100 versus placebo in HLA-A*02-positive, HER2-positive patients at high risk of recurrence after specified neoadjuvant and postoperative trastuzumab-based treatment. Trial design, enrollment, statistical plan, interim analysis, adaptive features and manufacturing details remained under FDA discussion and could change.
- Management was completing clinical drug-product manufacturing and preparing to open trial sites. The company estimated that completing an interim analysis and filing a U.S. biologics license application could cost more than $30 million; the estimate and trial budget depend on design and execution.
- In the completed Phase IIb trial, the company reported no recurrences among GLSI-100-treated HER2 3+ patients in the defined efficacy population after median five-year follow-up, versus an 11% recurrence rate in the placebo group (p=0.0338). The efficacy population excluded patients who did not remain disease-free through the first six months. The filing also says no recurrence-rate reduction was observed in the HER2 1–2+ population.
- Across four clinical trials, 146 patients had received GP2; the company reported no serious adverse events attributed to the immunotherapy. These are company-reported earlier-stage findings and do not establish Phase III efficacy or regulatory approval.
Outlook, risks and unusual items
- The company expects continued losses and significant expenses, with no revenue expected for many years, if at all. Additional capital is needed; no committed financing source was disclosed. Equity financing could dilute shareholders, while other arrangements could require surrendering valuable rights.
- Key risks include Phase III design agreement and execution, patient recruitment, regulatory approval, manufacturing scale-up and reliance on third-party suppliers. GM-CSF is available from one manufacturer, and the company reported no supply agreement for it. HLA typing will require a companion diagnostic, which the company had not developed with an approved collaborator.
- GP2 rights are licensed exclusively from the Henry M. Jackson Foundation. The license requires maintenance fees, milestone payments of up to $5.7 million, sales royalties of 2.5%–5% and patent-expense reimbursement. The company reported paying HJF $434,732 in 2021 for maintenance fees and patent expenses; no milestone or royalty payments had been required to date.
- Management concluded that disclosure controls and internal control over financial reporting were ineffective at December 31, 2021, citing inadequate segregation of duties and insufficient written accounting, IT and reporting procedures due to limited personnel. A remediation plan was in development. The auditor gave an unqualified opinion on the financial statements but was not engaged to audit internal controls.
- Subsequent event: A January 2022 repurchase authorization allowed up to $10 million in buybacks. By March 15, approximately 269,828 shares had been repurchased for about $5.51 million, after which the program was indefinitely suspended. Consider this alongside the stated cash runway and Phase III funding needs.
- The filing reported no material legal proceedings and no off-balance-sheet arrangements. It disclosed that directors, executive officers and principal stockholders beneficially owned approximately 70% of shares as of March 21, 2022.
Investor verification points
- Confirm the Phase III protocol, FDA alignment, start date, enrollment target, interim-analysis plan, projected timeline and total funding requirement.
- Review the Phase IIb efficacy-population definition, denominators and subgroup analysis; reconcile the filing’s descriptions of the HER2 3+ patient counts and comparison groups.
- Assess cash and expected burn after the 2022 repurchases, and identify committed financing sufficient to advance the trial.
- Verify GMP manufacturing readiness and continuity of supply for GP2 and single-source GM-CSF, as well as the HLA companion-diagnostic plan.
- Track remediation of the disclosed internal-control material weaknesses and the status of management’s stated cash-runway estimate.